Recombinant Vaccine Market, By Type (Attenuated Recombinant Vaccines, Vector Recombinant Vaccines, and Subunit Recombinant Vaccines), By Indication (Human Papillomavirus (HPV), Meningococcal, Hepatitis B, Influenza, Rotavirus, Herpes Zoster, and Others),

The Global Recombinant Vaccine Market is estimated to be valued at USD 12.52 Bn in 2025 and is expected to reach USD 27.17 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 11.7% from 2025 to 2032.Recombinant vaccines are developed using recombinant DNA technology by combining genes that code for vaccine antigens with the genes of another organism like yeast, bacteria, or viruses. The recombinant genes are then transferred into host cells which are then cultured in large fermenters to produce antigen proteins. Recombinant technology overcomes many limitations of conventional vaccine production as antigens can be mass produced in precisely controlled conditions regardless of season or disease outbreak. With benefits of low production cost, high yield and scalability, the global recombinant vaccine market is expected to experience significant growth over the forecast period.

Market Dynamics:

The global recombinant vaccine market is projected to witness robust growth attributable to factors such as increasing prevalence of infectious diseases, rising awareness about vaccination, and technological advancement in recombinant DNA production techniques. However, high development costs and stringent regulatory framework are expected to impede the market growth. On the other hand, emerging economies with large untapped populations present lucrative opportunities for manufacturers. Market players are investing in R&D to develop vaccines for new disease indications as well as combination vaccines which provide an opportunity for additional vaccination during well-child visits, thereby improving patient compliance.

Key Features of the Study:

• This report provides in-depth analysis of the global recombinant vaccine market and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global recombinant vaccine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Merck & Co., Inc., Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson, Novavax, Inc., AstraZeneca Plc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Emergent BioSolutions Inc., Bharat Biotech, Protein Sciences Corporation, VBI Vaccines Inc., and Inovio Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global recombinant vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant vaccine market

• By Type Insights (Revenue, USD Bn, 2020 - 2032)
• Attenuated Recombinant Vaccines
• Vector Recombinant Vaccines
• Subunit Recombinant Vaccines
• By Indication Insights (Revenue, USD Bn, 2020 - 2032)
• Human Papillomavirus (HPV)
• Meningococcal
• Hepatitis B
• Influenza
• Rotavirus
• Herpes Zoster
• Others
• By End User Insights (Revenue, USD Bn, 2020 - 2032)
• Pediatric
• Adult
• Geriatric
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Hospital & Retail Pharmacies
• Government Suppliers
• Vaccination Centers
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Merck & Co., Inc.
• Sanofi S.A.
• Pfizer Inc.
• GlaxoSmithKline Plc.
• Johnson & Johnson
• Novavax, Inc.
• AstraZeneca Plc.
• Dynavax Technologies Corporation
• Serum Institute of India Pvt. Ltd.
• Emergent BioSolutions Inc.
• Bharat Biotech
• Protein Sciences Corporation
• VBI Vaccines Inc.
• Inovio Pharmaceuticals, Inc.